Replies to post #99421 on Biotech Values

[read_this_n0w]

Ok i was unaware of the similarity. So if the IP holding company agrees, than this is indeed a viable way to go forward ?

With the advantages a patient advocacy group has over pharma company?

Must say the tech transfer percentage as well as the royalty still makes it commercially interesting for the IP holder as well.